Relatively new to the therapeutic landscape, oral semaglutide is the first and only available non-injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA). In this audio activity, you will learn about the nuances of using this unique formulation in clinical practice.
After completing this activity, participants should be better able to:
- Partner with patients to use shared decision-making to select and improve adherence to therapies
NPs and PAs
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Nursing contact hours: 0.25, which includes 0.25 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credit. Approval is valid until August 14, 2021. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This activity is supported by an educational grant from Novo Nordisk Inc.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Ms Kruger:advisory board: Eli Lilly and Company, Merck, Sanofi-Aventis; advisory board/research support/speakers bureau: Abbott, Dexcom, Novo Nordisk; advisory board/speakers bureau: BI-Lilly, Janssen; advisory board/stock: Pendulum Therapeutics; research support: The Leona M. and Harry B. Helmsley Charitable Trust, Lexicon Pharmaceuticals; speakers bureau: AstraZeneca, Insulet, Lilly, Valeritas.
None of the members of the PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Listen to the content in its entirety
- Relate the content material to the learning objective
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 75%.
The estimated time to complete this activity is 15 minutes.
Release date: August 15, 2020
Expiration date: August 14, 2021
© 2021 Practicing Clinicians Exchange. All Rights Reserved. 97220CPCE-M3